Erratum: Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial (JAMA Oncol. (2021) 7:2 (271-278) DOI: 10.1001/jamaoncol.2020.6741)

K. Kalinsky, F. Hong, C. K. McCourt

Research output: Contribution to journalComment/debate

Abstract

Error in the Abstract: In the Original Investigation titled, “Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial,” which published online December 30, 2020, and in print in the February 2021 issue,1 the trial registration information was incorrect. The correct ClinicalTrials.gov identifier is NCT04439123. This article was corrected online.

Original languageEnglish
Pages (from-to)1729
Number of pages1
JournalJAMA oncology
Volume7
Issue number11
DOIs
StatePublished - Nov 2021

Fingerprint

Dive into the research topics of 'Erratum: Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial (JAMA Oncol. (2021) 7:2 (271-278) DOI: 10.1001/jamaoncol.2020.6741)'. Together they form a unique fingerprint.

Cite this